Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Abstract
Comprehensive protection of a patient with atrial fibrillation (AF) should not only reduce the risk of stroke and systemic embolism, but also reduce the risk coronary events and ensure high adherence to treatment. In accordance with consensus document issued by the European Heart Rhythm Association, European Society of Cardiology, European Association of Percutaneous Cardiovascular Interventions, as well as with other recent Russian Society of Cardiology Guidelines, the management of antithrombotic therapy of patients with AF undergoing percutaneous coronary intervention (PCI) requires that multiple and interconnected issues. The review article addresses questions about duration of initial triple antithrombotic therapy (TAT), selection of P2Y12 inhibitor, choice of oral anticoagulant to be combined with antiplatelet therapy, intensity of oral anticoagulation throughout combination therapy, and choice of oral anticoagulant for indefinite therapy. In general, it is recommended to refuse the routine use of TAT for most patients. Accordingly, for patients who need both anticoagulant and antiplatelet therapy, it is strongly recommended that the default strategy after recent PCI is a double antithrombotic therapy consisting of an anticoagulant and one antiplatelet, preferably from the group of P2Y12 inhibitors. When conducting combined antithrombotic therapy, preference should be given to clopidogrel compared to other, more powerful P2Y12 inhibitors and direct oral anticoagulant (DOAC) instead of vitamin K antagonists. The primary choice of DOAC in patients with AF who have undergone PCI should be carried out taking into account such factors as individual risk of stroke and bleeding, adherence to treatment, concomitant diseases, pharmacological characteristics and evidence base of a specific DOAC, taking other medications, etc. The pharmacokinetic features of rivaroxaban, which create the possibility of its single administration, the evidence base for reducing coronary risks in various variants of the course of coronary heart disease, determines the special positions of the drug for the comprehensive protection of patients with AF after PCI.
About the Author
A. V. Panov
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Alexey V. Panov
eLibrary SPIN 5103-6363
Saint Petersburg
References
1. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11(4):423-34. DOI:10.1093/europace/eun369.
2. Steinberg BA, Kim S, Piccini JP, et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013;128(7):721-8. DOI:10.1161/CIRCULATIONAHA.113.002927.
3. Fox KAA, Velentgas P, Camm AJ, et al. Outcomes associated with oral anticoagulants plus antiplatelets in patients with newly diagnosed atrial fibrillation. JAMA Netw Open. 2020;3(2):e200107. DOI:10.1001/jamanetworkopen.2020.0107.
4. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26(22):2422-34. DOI:10.1093/eurheartj/ehi505
5. Steffel1 Y, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Apr 25;euab065. DOI: 10.1093/europace/euab065.
6. Depta JP, Cannon CP, Fonarow GC, et al. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009;104(9):1171-8. DOI:10.1016/j.amjcard.2009.06.027.
7. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-17. DOI:10.1056/NEJMoa1107039.
8. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-12. DOI:10.1016/S01406736(06)68845-4.
9. Leon MB, Baim DS, Popma JJ, et al., Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998; 339(23):1665-71. DOI:10.1056/NEJM199812033392303.
10. Dentali F, Douketis JD, Lim W, et al. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med. 2007;167(2):117-24. DOI:10.1001/archinte.167.2.117.
11. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433-41. DOI:10.1001/archinternmed.2010.271.
12. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509-24. DOI:10.1056/NEJMoa1817083.
13. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107-15. DOI:10.1016/S01406736(12)62177-1.
14. Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015;169(4):472-8.e5. DOI:10.1016/j.ahj.2014.12.006.
15. Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513-24. DOI:10.1056/NEJMoa1708454.
16. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxabanbased versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients withatrial fibrillation (ENTRUSTAF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335-43. DOI:10.1056/NEJMoa1708454.
17. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127(5):634-40. DOI:10.1161/CIRCULATIONAHA.112.115386.
18. Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summa-ry. Circ Cardiovasc Interv. 2011;4(5):522-34. DOI:10.1161/CIRCINTERVENTIONS.111.965186.
19. Paikin JS, Wright DS, Crowther MA, et al. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation. 2010;121(18):2067-70. DOI:10.1161/CIRCULATIONAHA.109.924944.
20. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32(15):1854-64. DOI:10.1093/eurheartj/ehr204.
21. Fiedler K.A., Maeng M., Mehilli J., et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015;65(16):1619-29. DOI:10.1016/j.jacc.2015.02.050.
22. Atrial fibrillation and flutter. Guidelines of the Russian Society of Cardiology (2020) [cited by Jun 30, 2021. Available from: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf (In Russ.)
23. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. (In Russ.) DOI:10.15829/1560-4071-2020-4103.
24. Acute Coronary Syndrome without Persistent ST Elevation. Guidelines of the Russian Society of Cardiology (2020). Russian Journal of Cardiology. 2020;26(4):4449 (In Russ.. DOI:10.15829/1560-4071-2021-4449.
25. Stable ischemic heart disease. Guidelines of the Russian Society of Cardiology (2020). Russian Journal of Cardiology. 2020;25(11):201-51 (In Russ.). DOI: 10.15829/1560-4071-2020-4076.
26. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.
27. Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;77(5):629-58. DOI:10.1016/j.jacc.2020.09.011.
28. Lopes RD, Leonardi S, Wojdyla DM, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. Circulation. 2019;141(9):781-3. DOI:10.1161/CIRCULATIONAHA.119.044584.
29. Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2018;138(5):527-36. DOI:10.1161/CIRCULATIONAHA.120.050438.
30. Lip GYH, Collet JP, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the EHRA, EAPCI, ACCA endorsed by the HRS, APHRS, LAHRS, CASSA. Europace. 2019;21(2):192-3. DOI:10.1093/europace/euy174.
31. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100-9. DOI:10.1056/NEJMoa1209979.
32. Price MJ, Berger PB, Teirstein PS, et al. Standardvs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097-105. DOI:10.1001/jama.2011.290.
33. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59(24):2159-64. DOI:10.1016/j.jacc.2012.02.026.
34. Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621-31. DOI:10.1056/NEJMoa1907096.
35. Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381():1103-13. DOI:10.1056/NEJMoa1904143.
36. Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation. 2019;139(5):604-16. DOI:10.1161/CIRCULATIONAHA.118.036768.
37. Berry NC, Mauri L, Steg PG, et al. Effect of lesion complexity and clinical risk factors on the efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: a subgroup analysis from the REDUAL PCI trial. Circ Cardiovasc Interv. 2020;13(4):e008349. DOI:10.1161/CIRCINTERVENTIONS.119.008349.
38. Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008;102(12):1618-23. DOI:10.1016/j.amjcard.2008.08.021.
39. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebocontrolled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. DOI:10.1038/clpt.2010.219.
40. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-44. DOI:10.1001/jama.2009.261.
41. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-17. DOI:10.1056/NEJMoa1007964.
42. Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents,and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6(12):1267-74. DOI:10.1016/j.jcin.2013.06.015.
43. Rubboli A, Lip GYH. Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):197-8. DOI:10.1093/ehjcvp/pvaa003.
44. Baker NC, O’Connell EW, Htun WW, et al. Safety of coronary angiography andpercutaneous coronary intervention via the radial versus femoral route inpatients on uninterrupted oral anticoagulation with warfarin. Am Heart J. 2014;168(4):537-44. DOI:10.1016/j.ahj.2014.06.016.
45. Chongprasertpon N, Zebrauskaite A, Coughlan JJ, et al. Performing diagnostic radial access coronary angiog-raphy on uninterrupted direct oral anticoagulant therapy: a prospective analysis. Open Heart. 2019;6(1):e0010. DOI:10.1136/openhrt-2019-001079.
46. Giustino G, Chieffo A, Palmerini T et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 2016;68(17):1851-64. DOI:10.1016/j.jacc.2016.07.760.
47. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. DOI:10.1093/eurheartj/ehy394.
48. Knuuti J, Wijns W, Saraste A, Capodanno D, et al. ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis a management of chronic coronary syndromes. Eur Heart J. 2020;41(3):40777. DOI:10.1093/eurheartj/ehz425
49. Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. DOI:10.1056/NEJMoa0904327.
50. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. DOI:10.1056/NEJMoa0706482.
51. Jackson LR, Ju C, Zettler M, Messenger JC, et al. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study. ACC Cardiovasc Interv. 2015;8(14):1880-9. DOI:10.1016/j.jcin.2015.08.018.
52. Valgimigli M, Bueno H, Byrne RA, et al. ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the ESC and of the EACTS. Eur Heart J. 2018;39(3):213-60. DOI:10.1093/eurheartj/ehx419.
53. Lau WCY, Douglas IJ, Wong ICK, et al. Thromboembolic, bleeding, and mortalityrisks among patients with nonvalvular atrial fibrillation treated with dual antiplatelet therapy versus oral anticoagulants: a population-based study. Heart Rhythm. 2020;17(1):33-40. DOI:10.1016/j.hrthm.2019.07.034.
54. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin inpatients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. DOI:10.1016/S0140-6736(13)62343-0.
55. Genereux P, Giustino G, Witzenbichler B, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015;66(9):1036-45. DOI:10.1016/j.jacc.2015.06.1323.
56. ten Berg JM, de Veer A, Oldgren J, Steg PG, et al. RE-DUAL PCI Steering Committee and Investigators. Switching of oral anticoagulation therapy after PCI in patients with atrial fibrillation: the RE-DUAL PCI trial subanalysis. JACC Cardiovasc Interv. 2019;12(23):2331-41. DOI:10.1016/j.jcin.2019.08.039.
57. Rubboli A, Valgimigli M, Capodanno D, et al. Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence. Eur Heart J – Cardiovascular Pharmacotherapy. 2021;7(1):68-73. DOI:10.1093/ehjcvp/pvaa047.
58. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin inpatients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. DOI:10.1016/S0140-6736(13)62343-0.
59. Rubboli A, Lisi M. After the AUGUSTUS trial, should apixaban be the only directoral anticoagulant to be used in triple therapy in atrial fibrillation patients under-going percutaneous coronary intervention? Cardiovasc Drugs Ther. 2019;33(4):499-500. DOI:10.1007/s10557-019-06886-w.
60. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e326S-e350S. DOI:10.1378/chest.11-2298.
61. Eikelboom JW, Connolly S J, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377(14):1319-1330. DOI:10.1056/NEJMoa1709118.
62. Mega J, Braunwald E, Wiviott S, et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012;366(1):9-19. DOI:10.1056/NEJMoa1112277.
63. Pradaxa. Summary of product characteristics. European Medicines Agency DSoPC [cited by Jun 30, 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf.
64. van Es RF, Jonker JJ, Verheugt FW, et al. Antithrombotics in the Secondary Prevention of Events in CoronaryThrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360(9327):109-13. DOI:10.1016/S0140-6736(02)09409-6.
65. Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347(13):969-74. DOI:10.1056/NEJMoa020496.
66. Hamon M, Lemesle G, Tricot O, et al. Incidence, source, determinants, and prognostic im-pact of major bleeding in outpatients with stable coronary artery disease. J Am Coll Cardiol. 2014;64(14):1430-6. DOI:10.1016/j.jacc.2014.07.957.
67. Yasuda S, Kaikita K, Akao M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019;381(12):1103-13. DOI:10.1056/NEJMoa1904143.
Review
For citations:
Panov A.V. Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Rational Pharmacotherapy in Cardiology. 2021;17(4):628-637. (In Russ.) https://doi.org/10.20996/1819-6446-2021-07-02
Views: 342
Email this article 